Xgeva: osteoclast-targeting agent for malignant fractures

Xgeva (denosumab) has been launched for the prevention of skeletal events due to bone metastases from solid tumours.

Subcutaneous injection to prevent skeletal events
Subcutaneous injection to prevent skeletal events

Denosumab is a fully human monoclonal antibody specific for the RANK ligand, which is essential for the differentiation, function and survival of osteoclasts. Denosumab is already licensed as Prolia to treat bone loss in postmenopausal women and in men with prostate cancer.

Three randomised, double-blind studies assessed the capacity of denosumab, given as a 120mg subcutaneous injection every four weeks, to prevent events such as pathological fracture and spinal cord compression in 5723 patients with advanced malignancies. The studies enrolled patients with breast cancer, prostate cancer, and other solid tumours or multiple myeloma.

Compared with zoledronic acid, denosumab increased the median time to the first skeletal-related event by 8.2 months (from 19.4 months to 27.6 months; p<0.0001). Overall survival and time to pain improvement were similar for the two agents.

View Xgeva drug record

Further Information: Amgen

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Logo of the webinar

Cow's Milk Allergy in Practice: free webinar series for UK healthcare professionals

Join us for a short webinar series offering insights...

Close up image of multicoloured capsules

MIMS antidepressants table updated

The MIMS table 'Antidepressants, a guide to switching...

Purple, orange, blue and yellow blood test tubes on a tray.

New advice on vitamin B12 monitoring in patients taking metformin

Patients on metformin treatment with risk factors for...